Table 1 Baseline clinical parameters
|  | All patients (n = 42) | Cardiac sarcoidosis (n = 13) | Not cardiac sarcoidosis (n = 29) | P value |
|---|---|---|---|---|
Age, year | 53 ± 13 | 59 ± 11 | 50 ± 14 | 0.039 |
Women, n (%) | 14 (33%) | 4 (31%) | 10 (34%) | 0.99 |
Body surface area, m2 | 2.0 ± 0.2 | 2.0 ± 0.2 | 2.0 ± 0.2 | 0.30 |
Systolic blood pressure, mmHg | 124 ± 19 | 129 ± 23 | 121 ± 17 | 0.24 |
Diastolic blood pressure, mmHg | 75 ± 10 | 79 ± 10 | 74 ± 10 | 0.20 |
Symptomatic, n (%) | 24 (57%) | 10 (77%) | 14 (48%) | 0.10 |
Final diagnosis | ||||
Cardiac sarcoidosis | 13 (31%) | 13 (100%) | – |  |
Extra-cardiac sarcoidosis with no cardiac involvement | 10 (24%) | – | 10 (34%) |  |
Myocarditis | 7 (17%) | – | 7 (24%) |  |
Non-ischemic/inflammatory cardiomyopathy | 12 (29%) | – | 12 (41%) |  |
Risk factors | ||||
Smoking history, n (%) | 14 (33%) | 7 (54%) | 7 (24%) | 0.08 |
Hypertension, n (%) | 19 (45%) | 7 (54%) | 12 (41%) | 0.52 |
Diabetes mellitus, n (%) | 10 (24%) | 2 (15%) | 8 (28%) | 0.47 |
Hypercholesterolemia, n (%) | 18 (43%) | 7 (54%) | 11 (38%) | 0.50 |
Medications | ||||
Beta blocker, n (%) | 22 (53%) | 7 (54%) | 15 (52%) | 0.99 |
ACE inhibitor, n (%) | 12 (29%) | 4 (31%) | 8 (28%) | 0.99 |
ARB, n (%) | 6 (14%) | 2 (15%) | 4 (14%) | 0.99 |
Immune suppression therapy, n (%) | 6 (14%) | 2 (15%) | 4 (14%) | 0.99 |
Corticosteroids, n (%) | 6 (14%) | 2 (15%) | 4 (14%) | 0.99 |
Methotrexate, n (%) | 2 (5%) | 1 (8%) | 1 (3%) | 0.53 |